{
    "nct_id": "NCT03234556",
    "official_title": "Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-center, MR-Guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer",
    "inclusion_criteria": "* Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information\n\n  * Note: HIPAA authorization may be included in the informed consent or obtained separately\n* Eastern Cooperative Oncology Group (ECOG) performance status of =< 1 within 3 months (93 days) prior to being registered for protocol\n* African-American or white men (Hispanic or non-Hispanic)\n* Prostate biopsy-naive or a single negative biopsy\n* Having elevated prostate specific antigen (PSA) (> 2.5 ng/ml) and no palpable nodule on digital rectal exam (DRE)\n* Ability to understand the willingness to sign a written informed consent\n* Patients must be willing to undergo a radiologic imaging before and after biopsy of the prostate\n* Patients must be willing to undergo a biopsy of the prostate\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 40 Years",
    "exclusion_criteria": "* Patients who have had chemotherapy or radiotherapy within 12 months of the study for other diagnoses not related to prostate cancer\n* Patients receiving any other investigational agents\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Patients with active inflammatory bowel disease\n* Patients who are unable to undergo MRI\n* Patients who had any surgery of the prostate including TURP (transurethral resection of the prostate)\n* Patients who had > 1 prior prostate biopsy",
    "miscellaneous_criteria": ""
}